ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Catheter Precision, Inc. Announces New Clinical Data Presented at SCRN

FORT MILL, SC / ACCESSWIRE / November 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced that new clinical data from the VIVO EU Registry was presented last week at the Society of Cardiac Robotic Navigation (SCRN) meeting in Lisbon, Portugal.

As previously announced, there were three presentations about VIVO during the SCRN meeting which took place October 28-29. The presentation by Professor Leonor Parreira shared the final data from Hospital da Luz. This center enrolled 27 subjects of which 18 proceeded with an ablation procedure with the following results:

  • 100% accurate identification of the site of origin to the exact or neighboring cardiac segment

  • 17 (≈95%) patients had successful ablation procedures

  • 83% of patients had no recurrence of the arrhythmia at 12 months post ablation

"100% accuracy continues to impress our current physicians while attracting new physicians, and we look forward to publishing the complete study results which will include data from seven additional studies", said David Jenkins, CEO of Catheter Precision. "VIVO has always proven to be accurate in clinical studies, but this is the first study where we have assessed patients at 12 months post ablation. This data is the first step in understanding how VIVO can impact not only the success of the ablation procedure but improve the decision making about moving forward with an ablation procedure and potentially the long-term outcomes for future patients."

About VIVO

Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

At the Company
David Jenkins
973-691-2000
IR@catheterprecision.com

# # #

Contact Information

Missiaen Huck
COO
mhuck@catheterprecision.com
9736912000

SOURCE: Catheter Precision, Inc.



View the original press release on accesswire.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  231.30
+0.30 (0.13%)
AAPL  247.65
+0.95 (0.39%)
AMD  249.66
+17.75 (7.65%)
BAC  52.07
-0.03 (-0.06%)
GOOG  328.38
+6.22 (1.93%)
META  612.96
+8.84 (1.46%)
MSFT  444.06
-10.46 (-2.30%)
NVDA  183.18
+5.11 (2.87%)
ORCL  173.88
-6.04 (-3.36%)
TSLA  431.44
+12.19 (2.91%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.